Bullish indicating open at $55-$60, IPO prices at $37
ALT5 Sigma Corporation (ALTS) announced its support for the GENIUS Act, new U.S. legislation establishing a regulatory framework for stablecoin issuance and oversight. The Las Vegas-based fintech company provides blockchain-powered payment and trading infrastructure for merchants and financial institutions.
"We believe this legislation marks a turning point," said Peter Tassiopoulos, CEO of ALT5 Sigma. "With a clear legal foundation now in place, U.S. enterprises can finally build with confidence and unlock the transformative capabilities of blockchain."
The company stated its infrastructure was designed to support compliant digital asset adoption and views the legislation as aligning with principles now being codified in law. Stablecoins processed $27.6 trillion in on-chain transactions during 2024, surpassing the combined annual volumes for Visa and Mastercard, according to the company.
ALT5 Sigma has processed over $5 billion in cryptocurrency transactions to date, supporting more than 1,000 businesses worldwide. The company reported accelerating demand for stablecoin-related infrastructure as enterprises seek to integrate blockchain-based payments into existing operations.
The company operates two main platforms: ALT5 Pay, a cryptocurrency payment gateway for merchants, and ALT5 Prime, an over-the-counter trading platform for digital assets. ALT5 Pay enables merchants to accept cryptocurrency payments with options to convert to fiat currency or receive payment in digital assets.
ALT5 Sigma is also advancing the separation of its biotech business, which will continue under Alyea Therapeutics Corporation. The biotech division focuses on developing non-addictive pain-relieving drugs, including JAN123, which has received FDA Orphan Drug Designation for Complex Regional Pain Syndrome treatment.